1
|
Sánchez-Chapul L, Santamaría A, Aschner M, Ke T, Tinkov AA, Túnez I, Osorio-Rico L, Galván-Arzate S, Rangel-López E. Thallium-induced DNA damage, genetic, and epigenetic alterations. Front Genet 2023; 14:1168713. [PMID: 37152998 PMCID: PMC10157259 DOI: 10.3389/fgene.2023.1168713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2023] [Accepted: 04/10/2023] [Indexed: 05/09/2023] Open
Abstract
Thallium (Tl) is a toxic heavy metal responsible for noxious effects in living organisms. As a pollutant, Tl can be found in the environment at high concentrations, especially in industrial areas. Systemic toxicity induced by this toxic metal can affect cell metabolism, including redox alterations, mitochondrial dysfunction, and activation of apoptotic signaling pathways. Recent focus on Tl toxicity has been devoted to the characterization of its effects at the nuclear level, with emphasis on DNA, which, in turn, may be responsible for cytogenetic damage, mutations, and epigenetic changes. In this work, we review and discuss past and recent evidence on the toxic effects of Tl at the systemic level and its effects on DNA. We also address Tl's role in cancer and its control.
Collapse
Affiliation(s)
- Laura Sánchez-Chapul
- Laboratorio de Enfermedades Neuromusculares, División de Neurociencias Clínicas, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City, Mexico
| | - Abel Santamaría
- Laboratorio de Aminoácidos Excitadores/Laboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Michael Aschner
- Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, United States
| | - Tao Ke
- Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, United States
| | - Alexey A. Tinkov
- Yaroslavl State University, Medical University (Sechenov University), Moscow, Russia
| | - Isaac Túnez
- Instituto de Investigaciones Biomédicas Maimonides de Córdoba, Departamento de Bioquímica Y Biología Molecular, Facultad de Medicina Y Enfermería, Red Española de Excelencia en Estimulación Cerebral (REDESTIM), Universidad de, Córdoba, Spain
| | - Laura Osorio-Rico
- Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Sonia Galván-Arzate
- Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
- *Correspondence: Edgar Rangel-López, ; Sonia Galván-Arzate,
| | - Edgar Rangel-López
- Laboratorio de Aminoácidos Excitadores/Laboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
- *Correspondence: Edgar Rangel-López, ; Sonia Galván-Arzate,
| |
Collapse
|
2
|
Meloni A, Montanaro D, De Marchi D, Resta M, Keilberg P, Pistoia L, Positano V, Spasiano A, Casini T, De Bari CC, De Cori S, Pepe A. Absence of T1 Hyperintensity in the Brain of High-risk Patients After Multiple Administrations of High-dose Gadobutrol for Cardiac Magnetic Resonance. Clin Neuroradiol 2021; 31:347-55. [PMID: 32185401 DOI: 10.1007/s00062-020-00897-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 02/28/2020] [Indexed: 10/24/2022]
Abstract
PURPOSE A prospective study was conducted to evaluate signal changes in the dentate nucleus, globus pallidus, pons, and thalamus (normalized to the deep cerebellum white matter) in T1-weighted magnetic resonance (MR) images after serial injections of gadobutrol in patients with thalassemia without neurological lesions. METHODS In this study three groups were scanned at both 1.5 T and 3 T: 15 thalassemia patients transfused and chelated with ≥4 gadobutrol administrations at a high dose (0.2 mmol/kg per scan) for late gadolinium enhancement (LGE) cardiovascular MR, 8 thalassemia patients and 13 healthy subjects who had never received gadolinium-based contrast agents (GBCA). RESULTS Signal intensity (SI) ratios at 1.5 T in all regions were comparable among the three groups and were not correlated with the number of gadobutrol administrations. In healthy subjects SI ratios were significantly different among the 4 regions, being higher in the pallidus. The SI ratios at 1.5 T were significantly higher and not correlated with SI ratios at 3 T or with iron overload in the same regions assessed by the T2* technique. CONCLUSION This article describes the lack of increased SI in T1-weighted MR images after repeated administration of gadobutrol for cardiovascular MR studies in a high-risk population (high dose per scan, iron overload that can facilitate the transmetalation of gadolinium) scanned at 3 T and 1.5 T.
Collapse
|
3
|
Salehi S, Saljooghi AS, Badiee S, Moqadam MM. Chelation of Thallium (III) in Rats Using Combined Deferasirox and Deferiprone Therapy. Toxicol Res 2017; 33:299-304. [PMID: 29071014 PMCID: PMC5654193 DOI: 10.5487/tr.2017.33.4.299] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 04/06/2017] [Accepted: 07/07/2017] [Indexed: 01/07/2023] Open
Abstract
Thallium and its compounds are a class of highly toxic chemicals that cause wide-ranging symptoms such as gastrointestinal disturbances; polyneuritis; encephalopathy; tachycardia; skin eruptions; hepatic, renal, cardiac, and neurological toxicities; and have mutagenic and genotoxic effects. The present research aimed to evaluate the efficacy of the chelating agents deferasirox (DFX) and deferiprone (L1) in reducing serum and tissue thallium levels after the administration of thallium (III), according to two different dosing regimens, to several groups of Wistar rats for 60 days. It was hypothesized that the two chelators might be more efficient as a combined therapy than as monotherapies in removing thallium (III) from the rats' organs. The chelators were administered orally as either single or combined therapies for a period of 14 days. Serum and tissue thallium (III) and iron concentrations were determined by flame atomic absorption spectroscopy. Serum and tissue thallium (III) levels were significantly reduced by combined therapy with DFX and L1. Additionally, iron concentrations returned to normal levels and symptoms of toxicity decreased.
Collapse
Affiliation(s)
- Samie Salehi
- Department of Chemistry, Ferdowsi University of Mashhad, Faculty of Science, Mashhad 91775-1436,
Iran
| | - Amir Sh. Saljooghi
- Department of Chemistry, Ferdowsi University of Mashhad, Faculty of Science, Mashhad 91775-1436,
Iran
| | - Somayeh Badiee
- Department of Chemistry, Ferdowsi University of Mashhad, Faculty of Science, Mashhad 91775-1436,
Iran
| | - Mojtaba Mashmool Moqadam
- Department of Chemistry, Ferdowsi University of Mashhad, Faculty of Science, Mashhad 91775-1436,
Iran
| |
Collapse
|
4
|
Amiri A, Mirhoseiny Z. Beneficial role of deferasirox and deferiprone in the mobilization of arsenic and recovery of iron in rat tissues. MGC 2017. [DOI: 10.3233/mgc-160215] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
5
|
Maximova N, Gregori M, Zennaro F, Sonzogni A, Simeone R, Zanon D. Hepatic Gadolinium Deposition and Reversibility after Contrast Agent-enhanced MR Imaging of Pediatric Hematopoietic Stem Cell Transplant Recipients. Radiology 2016; 281:418-426. [PMID: 27276243 DOI: 10.1148/radiol.2016152846] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Purpose To determine if hepatic gadolinium deposition occurs in pediatric patients with iron overload but normal renal and hepatic function who undergo gadolinium-based contrast agent (GBCA)-enhanced magnetic resonance (MR) imaging. Materials and Methods Design and execution of this study was approved by the Ethical Committee of Institute for Research in Maternal and Child Health Burlo Garofolo of Trieste (reference no. 1105/2015). Because of the retrospective nature of the study, the requirement to obtain informed consent was waived. Twenty-one recipients of allogeneic hematopoietic stem cell transplants who underwent GBCA-enhanced MR imaging for suspected infection or relapse followed by liver biopsy comprised the study group. The number of GBCA-enhanced MR examinations and cumulative gadolinium dose for each patient was analyzed by comparing liver histologic analysis and iron and gadolinium liver concentration (GLC). Eight patients had siderosis and underwent chelation therapy. The study group was compared with four control patients who were never exposed to GBCA. Statistical analysis was performed with Spearman rank coefficient for correlation. Results All 21 patients had positive correlations between GLC and total GBCA dose (r = 0.4486; P < .05) and between GLC and liver iron concentration (r = 0.56; P < .05). Patients who underwent deferoxamine therapy had a significant reduction of GLC (from 0.64 μg/g ± 0.29 to 0.20 μg/g ± 0.17 [standard deviation]; P < .05). Conclusion In the presence of siderosis, a transmetallation mechanism may be set off between ferric ion and gadoterate meglumine. Deferoxamine appears capable of binding to gadolinium ion. Further studies of the safety of GBCAs in severe siderosis are needed. Chelation should be considered in patients with iron overload and a history of GBCA exposure. © RSNA, 2016.
Collapse
Affiliation(s)
- Natalia Maximova
- From the Bone Marrow Transplant Unit (N.M.), Department of Radiology (M.G., F.Z.), Department of Transfusion Medicine (R.S.), and Department of Pharmacy (D.Z.), Institute for Maternal and Child Health-IRCCS Burlo Garofolo, via dell'Istria, 65/1, 34137 Trieste, Italy; and Department of Pathology, Ospedale Beato Papa Giovanni XXIII, Bergamo, Italy (A.S.)
| | - Massimo Gregori
- From the Bone Marrow Transplant Unit (N.M.), Department of Radiology (M.G., F.Z.), Department of Transfusion Medicine (R.S.), and Department of Pharmacy (D.Z.), Institute for Maternal and Child Health-IRCCS Burlo Garofolo, via dell'Istria, 65/1, 34137 Trieste, Italy; and Department of Pathology, Ospedale Beato Papa Giovanni XXIII, Bergamo, Italy (A.S.)
| | - Floriana Zennaro
- From the Bone Marrow Transplant Unit (N.M.), Department of Radiology (M.G., F.Z.), Department of Transfusion Medicine (R.S.), and Department of Pharmacy (D.Z.), Institute for Maternal and Child Health-IRCCS Burlo Garofolo, via dell'Istria, 65/1, 34137 Trieste, Italy; and Department of Pathology, Ospedale Beato Papa Giovanni XXIII, Bergamo, Italy (A.S.)
| | - Aurelio Sonzogni
- From the Bone Marrow Transplant Unit (N.M.), Department of Radiology (M.G., F.Z.), Department of Transfusion Medicine (R.S.), and Department of Pharmacy (D.Z.), Institute for Maternal and Child Health-IRCCS Burlo Garofolo, via dell'Istria, 65/1, 34137 Trieste, Italy; and Department of Pathology, Ospedale Beato Papa Giovanni XXIII, Bergamo, Italy (A.S.)
| | - Roberto Simeone
- From the Bone Marrow Transplant Unit (N.M.), Department of Radiology (M.G., F.Z.), Department of Transfusion Medicine (R.S.), and Department of Pharmacy (D.Z.), Institute for Maternal and Child Health-IRCCS Burlo Garofolo, via dell'Istria, 65/1, 34137 Trieste, Italy; and Department of Pathology, Ospedale Beato Papa Giovanni XXIII, Bergamo, Italy (A.S.)
| | - Davide Zanon
- From the Bone Marrow Transplant Unit (N.M.), Department of Radiology (M.G., F.Z.), Department of Transfusion Medicine (R.S.), and Department of Pharmacy (D.Z.), Institute for Maternal and Child Health-IRCCS Burlo Garofolo, via dell'Istria, 65/1, 34137 Trieste, Italy; and Department of Pathology, Ospedale Beato Papa Giovanni XXIII, Bergamo, Italy (A.S.)
| |
Collapse
|
6
|
|
7
|
Balooch FD, Fatemi SJ, Iranmanesh M. Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model. Biometals 2014; 27:89-95. [DOI: 10.1007/s10534-013-9689-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Accepted: 11/22/2013] [Indexed: 01/19/2023]
|
8
|
Nejad FK, Fatemi SJ, Sheibani V. An investigation of cobalt toxicity on blood parameters and evaluation of deferasirox and desferrioxamine chelators in removing cobalt from biological system. TOXIN REV 2013. [DOI: 10.3109/15569543.2013.853315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
9
|
Saljooghi AS, Babaie M, Mendi FD, Zahmati M, Saljooghi ZS. Chelation of thallium by combining deferasirox and desferrioxamine in rats. Toxicol Ind Health 2013; 32:83-8. [DOI: 10.1177/0748233713498442] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The hypothesis that two known chelators deferasirox (4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid) and desferrioxamine (DFO) might be more efficient as combined treatment than as monotherapies in removing thallium from the body was tested in a new acute rat model. 7-week-old male Wistar rats received chelators: deferasirox (orally), DFO (intraperitoneal; i.p.), or deferasirox + DFO as 75 or 150 mg/kg dose half an hour after a single i.p. administration of 8 mg thallium/kg body weight in the form of chloride. Serum thallium concentration, urinary thallium, and iron excretions were determined by graphite furnace atomic absorption spectrometry. Both chelators were effective only at the higher dose level, while DFO was more effective than deferasirox in enhancing urinary thallium excretion, deferasirox was more effective than DFO in enhancing urinary iron excretion. In the combined treatment group, deferasirox did not increase the DFO effect on thallium and DFO did not increase the effect of deferasirox on iron elimination. Our results support the usefulness of this animal model for preliminary in vivo testing of thallium chelators. Urinary values were more useful because of the high variability of serum results.
Collapse
Affiliation(s)
- Amir Shokooh Saljooghi
- Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Islamic Republic of Iran
| | - Maryam Babaie
- Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Islamic Republic of Iran
| | - Fatemeh Delavar Mendi
- Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Islamic Republic of Iran
| | - Maliheh Zahmati
- Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Islamic Republic of Iran
| | | |
Collapse
|
10
|
Iranmanesh M, Fatemi SJA, Golbafan MR, Dahooee Balooch F. Treatment of mercury vapor toxicity by combining deferasirox and deferiprone in rats. Biometals 2013; 26:783-8. [DOI: 10.1007/s10534-013-9656-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2013] [Accepted: 07/05/2013] [Indexed: 01/19/2023]
|
11
|
Iranmanesh M, Fatemi SJA, Ebrahimpour R, Dahooee Balooch F. Chelation of chromium(VI) by combining deferasirox and deferiprone in rats. Biometals 2013; 26:465-71. [DOI: 10.1007/s10534-013-9631-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2013] [Accepted: 05/02/2013] [Indexed: 01/19/2023]
|
12
|
Fatemi SJ, Saljooghi AS, Balooch FD, Iranmanesh M, Golbafan MR. Removal of cadmium by combining deferasirox and desferrioxamine chelators in rats. Toxicol Ind Health 2011; 28:35-41. [DOI: 10.1177/0748233711403192] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
An investigation was conducted to evaluate the ability of two chelators, deferasirox and desferrioxamine (DFO), in removing cadmium from biological system. The potential efficiency of those chelators were investigated after cadmium administration for 60 days following two dose levels of 20 and 40 mg/kg body weight daily to male rats. However, abnormalities were observed in clinical signs after cadmium administration, such as yellowish discoloration of hair, flaccid and hypotonic muscles, irritability, weakness and loss of weight. The hypothesis that the two chelators might be more efficient as combined therapy than single therapy in removing metal ions from the body was considered. In this way, two known chelators, deferasirox and DFO were chosen and tested in the acute rat model. The chelation therapy results show that deferasirox and DFO are able ?to remove cadmium ions from the body, while iron concentration returned to the normal level and symptoms are decreased.
Collapse
Affiliation(s)
| | | | | | - Marzieh Iranmanesh
- Department of Chemistry, Islamic Azad University, Kerman Branch, Kerman, Iran
| | | |
Collapse
|
13
|
Jamilaldin Fatemi S, Amir Shokooh Saljooghi, Faezeh Dahooee Balooch, Iranmanesh M, Mohammad Reza Golbafan. Chelation of cadmium by combining deferasirox and deferiprone in rats. Toxicol Ind Health 2011; 27:371-7. [DOI: 10.1177/0748233710388451] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The present research aimed to characterize the potential efficiency of two chelators after cadmium administration for 60 days following two dose levels of 20 and 40 mg/kg body weight daily to male rats. However, the hypothesis that the two chelators might be more efficient as combined therapy than as single therapy in removing cadmium from the body was considered. In this way, two known chelators deferasirox and deferiprone (L1) were chosen and tested in the acute rat model. Two chelators were given orally as a single or combined therapy for the period of a week. Cadmium and iron concentrations in various tissues were determined by graphite furnace and flame atomic absorption spectrometry methods, respectively. The combined chelation therapy results show that Deferasirox and L1 are able to remove cadmium ions from the body while iron concentration returned to the normal level and symptoms are also decreased.
Collapse
Affiliation(s)
- S. Jamilaldin Fatemi
- Chemistry Department, Shahid Bahonar University of Kerman, Kerman, Iran, , Chemistry Department, Azad University of Kerman, Kerman, Iran
| | | | | | | | | |
Collapse
|
14
|
Abstract
The present research aimed to characterize the potential efficiency of deferasirox in removing thallium after its administration for 30 days following two dose levels of 20 and 160 μm of thallium (III) chloride to male Wistar rats every day. After thallium administration some abnormal clinical signs such as red staining around the eyes, greenish mottling on the liver, weakness, loss of hair and weight, were observed in animals. Deferasirox was given orally to different groups of rats for a period of one week immediately after thallium administration. After chelation therapy, animals were killed by exsanguination from the abdominal aorta, and then thallium and iron concentrations in various tissues were determined by standard addition method. The chelation therapy results showed that deferasirox was able to remove thallium ions from the body and clinical symptoms were also reduced.
Collapse
Affiliation(s)
- Amir Sh Saljooghi
- Department of Chemistry, Shahid Bahonar University of Kerman, Faculty of Science, Kerman, Iran.
| | | |
Collapse
|